ID

19255

Descrizione

Trial Evaluating Three Fixed Dosages of Paliperidone Extended-Release (ER) Tablets and Olanzapine in the Treatment of Patients With Schizophrenia; ODM derived from: https://clinicaltrials.gov/show/NCT00078039

collegamento

https://clinicaltrials.gov/show/NCT00078039

Keywords

versioni (1)
  1. 15/12/16 15/12/16 -
Caricato su

15 dicembre 2016

DOI

Per favore, per richiedere un accesso.

Licenza

Creative Commons BY 4.0
Commenti del modello :

Puoi commentare il modello dati qui. Tramite i fumetti nei gruppi di articoli e articoli è possibile aggiungere commenti a quelli in modo specifico.

Torna ai commenti del modello
Commenti del gruppo di articoli per :

Commenti dell'articolo per :

Per scaricare i modelli di dati devi essere registrato. Per favore accesso o registrati GRATIS.

Eligibility Schizophrenia NCT00078039

Inglese

Eligibility Schizophrenia NCT00078039

1 moduli  
Inclusion Criteria
Descrizione

Inclusion Criteria

Alias
UMLS CUI
C1512693
double-blind phase: dsm-iv diagnosis of schizophrenia at least 1 year prior to screening
Descrizione

Schizophrenia disease length

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C0036341
UMLS CUI [1,2]
C0872146
experiencing an acute episode, with a total panss score at screening between 70 and 120
Descrizione

schizophrenic episode Positive and negative syndrome scale

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C1396838
UMLS CUI [1,2]
C0451383
agree to voluntary hospitalization for a minimum of 14 days
Descrizione

HOSPITALIZATION VOLUNTARY Duration Agreement

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C0745044
UMLS CUI [1,2]
C0449238
UMLS CUI [1,3]
C0680240
willing and able to fill out self-administered questionnaires
Descrizione

Questionnaires Self-Administered Completion

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C0034394
UMLS CUI [1,2]
C1519231
UMLS CUI [1,3]
C0205197
able to be compliant with self-administration of medication, or have consistent help/support available.
Descrizione

Pharmaceutical Preparations Self-Administered Compliance behavior

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C0013227
UMLS CUI [1,2]
C1519231
UMLS CUI [1,3]
C1321605
open-label extension phase: completed the 6 weeks of double-blind treatment or completed at least 21 days of treatment and discontinued due to lack of efficacy
Descrizione

Therapeutic procedure Double-Blind Method Complete | Therapeutic procedure Discontinued Lack of Efficacy

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C0087111
UMLS CUI [1,2]
C0013072
UMLS CUI [1,3]
C0205197
UMLS CUI [2,1]
C0087111
UMLS CUI [2,2]
C1444662
UMLS CUI [2,3]
C0235828
patient and investigator agree that open-label treatment is in the best interest of the patient.
Descrizione

Open Label Treatment Agreement

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C3640652
UMLS CUI [1,2]
C0680240
Exclusion Criteria
Descrizione

Exclusion Criteria

Alias
UMLS CUI
C0680251
double-blind phase: dsm-iv axis i diagnosis other than schizophrenia
Descrizione

Axis I diagnosis | Schizophrenia

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0270287
UMLS CUI [2]
C0036341
dsm-iv diagnosis of substance dependence within 6 months prior to screening evaluation (nicotine and caffeine dependence are not exclusionary)
Descrizione

Substance Dependence | Nicotine Dependence | Caffeine dependence

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0038580
UMLS CUI [2]
C0028043
UMLS CUI [3]
C1386553
history of tardive dyskinesia or neuroleptic malignant syndrome (nms)
Descrizione

Tardive Dyskinesia | Neuroleptic Malignant Syndrome

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0686347
UMLS CUI [2]
C0027849
history of any severe preexisting gastrointestinal narrowing (pathologic or iatrogenic)
Descrizione

Gastrointestinal stenosis Pathologic Pre-existing Severe | Gastrointestinal stenosis Iatrogenic Pre-existing Severe

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C0521587
UMLS CUI [1,2]
C1521733
UMLS CUI [1,3]
C2347662
UMLS CUI [1,4]
C0205082
UMLS CUI [2,1]
C0521587
UMLS CUI [2,2]
C0439669
UMLS CUI [2,3]
C2347662
UMLS CUI [2,4]
C0205082
previous history of lack of response (2 adequate trials) to any antipsychotic
Descrizione

Antipsychotic Agents Quantity | Poor response to treatment

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C0040615
UMLS CUI [1,2]
C1265611
UMLS CUI [2]
C1320680
significant risk of suicidal or violent behavior. open-label phase: at significant risk for suicidal or violent behavior
Descrizione

Suicidal behavior Risk Significant | Physical aggression Risk Significant | At risk for suicide Significant | At risk for violence Significant

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C1760428
UMLS CUI [1,2]
C0035647
UMLS CUI [1,3]
C0750502
UMLS CUI [2,1]
C0424323
UMLS CUI [2,2]
C0035647
UMLS CUI [2,3]
C0750502
UMLS CUI [3,1]
C0563664
UMLS CUI [3,2]
C0750502
UMLS CUI [4,1]
C0231418
UMLS CUI [4,2]
C0750502
received an injection of a depot antipsychotic since entry into the preceding double-blind phase.
Descrizione

Injection of depot antipsychotic agent

Tipo di dati

boolean

Alias
UMLS CUI [1]
C2585377
Ritorna all'inizio della pagina

Similar models

Eligibility Schizophrenia NCT00078039

1 moduli
Name
genere
Description | Question | Decode (Coded Value)
Tipo di dati
Alias
Item Group
C1512693 (UMLS CUI)
Schizophrenia disease length
Item
double-blind phase: dsm-iv diagnosis of schizophrenia at least 1 year prior to screening
boolean
C0036341 (UMLS CUI [1,1])
C0872146 (UMLS CUI [1,2])
schizophrenic episode Positive and negative syndrome scale
Item
experiencing an acute episode, with a total panss score at screening between 70 and 120
boolean
C1396838 (UMLS CUI [1,1])
C0451383 (UMLS CUI [1,2])
HOSPITALIZATION VOLUNTARY Duration Agreement
Item
agree to voluntary hospitalization for a minimum of 14 days
boolean
C0745044 (UMLS CUI [1,1])
C0449238 (UMLS CUI [1,2])
C0680240 (UMLS CUI [1,3])
Questionnaires Self-Administered Completion
Item
willing and able to fill out self-administered questionnaires
boolean
C0034394 (UMLS CUI [1,1])
C1519231 (UMLS CUI [1,2])
C0205197 (UMLS CUI [1,3])
Pharmaceutical Preparations Self-Administered Compliance behavior
Item
able to be compliant with self-administration of medication, or have consistent help/support available.
boolean
C0013227 (UMLS CUI [1,1])
C1519231 (UMLS CUI [1,2])
C1321605 (UMLS CUI [1,3])
Therapeutic procedure Double-Blind Method Complete | Therapeutic procedure Discontinued Lack of Efficacy
Item
open-label extension phase: completed the 6 weeks of double-blind treatment or completed at least 21 days of treatment and discontinued due to lack of efficacy
boolean
C0087111 (UMLS CUI [1,1])
C0013072 (UMLS CUI [1,2])
C0205197 (UMLS CUI [1,3])
C0087111 (UMLS CUI [2,1])
C1444662 (UMLS CUI [2,2])
C0235828 (UMLS CUI [2,3])
Open Label Treatment Agreement
Item
patient and investigator agree that open-label treatment is in the best interest of the patient.
boolean
C3640652 (UMLS CUI [1,1])
C0680240 (UMLS CUI [1,2])
Item Group
C0680251 (UMLS CUI)
Axis I diagnosis | Schizophrenia
Item
double-blind phase: dsm-iv axis i diagnosis other than schizophrenia
boolean
C0270287 (UMLS CUI [1])
C0036341 (UMLS CUI [2])
Substance Dependence | Nicotine Dependence | Caffeine dependence
Item
dsm-iv diagnosis of substance dependence within 6 months prior to screening evaluation (nicotine and caffeine dependence are not exclusionary)
boolean
C0038580 (UMLS CUI [1])
C0028043 (UMLS CUI [2])
C1386553 (UMLS CUI [3])
Tardive Dyskinesia | Neuroleptic Malignant Syndrome
Item
history of tardive dyskinesia or neuroleptic malignant syndrome (nms)
boolean
C0686347 (UMLS CUI [1])
C0027849 (UMLS CUI [2])
Gastrointestinal stenosis Pathologic Pre-existing Severe | Gastrointestinal stenosis Iatrogenic Pre-existing Severe
Item
history of any severe preexisting gastrointestinal narrowing (pathologic or iatrogenic)
boolean
C0521587 (UMLS CUI [1,1])
C1521733 (UMLS CUI [1,2])
C2347662 (UMLS CUI [1,3])
C0205082 (UMLS CUI [1,4])
C0521587 (UMLS CUI [2,1])
C0439669 (UMLS CUI [2,2])
C2347662 (UMLS CUI [2,3])
C0205082 (UMLS CUI [2,4])
Antipsychotic Agents Quantity | Poor response to treatment
Item
previous history of lack of response (2 adequate trials) to any antipsychotic
boolean
C0040615 (UMLS CUI [1,1])
C1265611 (UMLS CUI [1,2])
C1320680 (UMLS CUI [2])
Suicidal behavior Risk Significant | Physical aggression Risk Significant | At risk for suicide Significant | At risk for violence Significant
Item
significant risk of suicidal or violent behavior. open-label phase: at significant risk for suicidal or violent behavior
boolean
C1760428 (UMLS CUI [1,1])
C0035647 (UMLS CUI [1,2])
C0750502 (UMLS CUI [1,3])
C0424323 (UMLS CUI [2,1])
C0035647 (UMLS CUI [2,2])
C0750502 (UMLS CUI [2,3])
C0563664 (UMLS CUI [3,1])
C0750502 (UMLS CUI [3,2])
C0231418 (UMLS CUI [4,1])
C0750502 (UMLS CUI [4,2])
Injection of depot antipsychotic agent
Item
received an injection of a depot antipsychotic since entry into the preceding double-blind phase.
boolean
C2585377 (UMLS CUI [1])
Ritorna all'inizio della pagina 

Contatto

Si prega di utilizzare questo modulo per feedback, domande e suggerimenti per miglioramenti.

I campi contrassegnati da * sono obbligatori.

Aiuto

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial